VEGFA and neoplasm: Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, has been shown to reduce tumor vascular permeability, thereby improving drug delivery and increasing drug concentration within tumors (Wildiers et al., 2003; Dickson et al., 2007; Le et al., 2021).